


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+10.45%
-2.45%
-1.98%
-0.62%
-7.61%
ZTS
Zoetis
$125.84
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Pays a reliable dividend
ZTS Price Performance
$118.66 (+6.05%)
$142.12 (-11.46%)
$155.67 (-19.16%)
$170.42 (-26.16%)
ZTS has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Hit 52-week low

ZTS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Pays a reliable dividend
Future
Future

Earnings are forecast to grow
![]()
ZTS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ZTS Street Sentiment is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels
IRIX
IRIDEX
1.32
-4.35%
ZTS
Zoetis
125.84
+0.98%
CDLX
Cardlytics Comm
1.29
+5.74%
CSIQ
Canadian Solar
20.85
-5.14%
LUNG
Pulmonx Corporation
2.00
+2.56%
What is ZTS current stock price?
What are ZTS stock strengths?
What is ZTS Risk Level?
What is ZTS market cap and volume?
What is ZTS current Stock IQ?
Should I buy ZTS stock right now?
Is ZTS a Strong Buy right now?
What does a 'Strong Buy' rating mean for ZTS?
What does a 'Strong Sell' rating mean for ZTS?
What factors influence ZTS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+10.45%
-2.45%
-1.98%
-0.62%
-7.61%
ZTS
Zoetis
Current Price
$125.84
ZTS Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Pays a reliable dividend
Recently Viewed
IRIX
IRIDEX
1.32
-4.35%
ZTS
Zoetis
125.84
+0.98%
CDLX
Cardlytics Comm
1.29
+5.74%
CSIQ
Canadian Solar
20.85
-5.14%
LUNG
Pulmonx Corporation
2.00
+2.56%

ZTS Price Performance
$118.66 (+6.05%)
$142.12 (-11.46%)
$155.67 (-19.16%)
$170.42 (-26.16%)
ZTS Analysts Opinion
ZTS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Pays a reliable dividend
Future
Future

Earnings are forecast to grow
![]()
ZTS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ZTS Street Sentiment is unimpressive and have negative views on the near-term outlook
ZTS has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Hit 52-week low

Average key support and resistance price levels
ZTS Latest Analysis
Zoetis: Cheap Valuation And Attractive Product Launch Pipeline.
Today
BofA Downgrades Zoetis (ZTS) to Neutral Cuts Price Target. Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15 BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165. In other news on December 5 Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for [….]
Tue Dec 30, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.